ArriVent inks ADC deal with Alphamab; Annexon’s $125M offering

Plus, news about Equillium and Structure Therapeutics:

ArriVent, Alphamab team up on multi-ADC collab: The companies will work together to develop …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Another recall: does Philips have a quality control problem? – Pharmaceutical Technology

Share this article Philips has recalled a number of high-profile medical devices in recent years, raising questions about its quality control. Photo: Sem van der

February 9, 2024

GlycoMimetics’ AML drug flunks Phase 3 trial, quashing filing plans as stock sinks

GlycoMimetics’ stock $GLYC tanked over 60% in premarket trading Monday morning after the biotech announced a Phase 3 trial failure for its lead drug, uproleselan,

May 7, 2024

2seventy bio fires 40% of staff after reduced Abecma sales forecasts – Pharmaceutical Technology

Despite restructuring news, the company’s stock rose by 6% in pre-market trading. Image Credit: ProStockStudio / Shutterstock. 2seventy bio will be reducing its workforce by

September 12, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.